SLCO1B1 and cancer: To evaluate the ability of the chimeric construct to sensitize cancer cells to cytostatic OATP1B1 substrates, a dose-dependent study was carried out in Alexander cells incubated with the desired antitumor drug from 48 h after the transiently transfection (Figure 3), based on the results obtained in the time-course of OATP1B1 expression described above (Figure 2A).